RBC Capital Mkts initiated coverage on QuidelOrtho with a new price target
$QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
RBC Capital Mkts initiated coverage of QuidelOrtho with a rating of Outperform and set a new price target of $125.00